222. Primary nephrotic syndrome
234 clinical trials,   241 drugs   (DrugBank: 78 drugs),   59 drug target genes,   185 drug target pathways

Searched query = "Primary nephrotic syndrome", "Minimal change nephrotic syndrome", "MCNS", "Membranous nephropathy", "Focal segmental glomerulosclerosis", "FSGS", "Membranoproliferative glomerulonephritis", "MPGN"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00801463
(ClinicalTrials.gov)
January 20092/12/2008Prednisone Plus Tripterygium Wilfordii Treatment of Adult Patients With Idiopathic Focal Segmental GlomerulosclerosisPrednisone Plus Tripterygium Wilfordii Treatment of Adult Patients With Idiopathic Focal Segmental GlomerulosclerosisProteinuria;Focal Segmental GlomerulosclerosisDrug: tripterygium wilfordii (TW)Nanjing University School of MedicineNULLCompleted18 Years60 YearsBoth67N/AChina
2NCT00518219
(ClinicalTrials.gov)
July 200716/8/2007To Compare the Efficacy and Safety of Tripterygium Wilfordii (TW) Versus Valsartan in the Membranous Nephropathy (MN)To Compare the Efficacy and Safety of TW vs Valsartan in the MNMembranous NephropathyDrug: TWNanjing University School of MedicineNULLCompleted18 Years65 YearsBoth68Phase 4China